Abstract: An 9-(2-hydroxypyridin-3-yl)-10-(2-hydroxyethyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
October 31, 2023
Date of Patent:
October 29, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
Abstract: The method of treating adenoid cystic carcinoma or other cancer tumors includes the administration of an effective dosage of an inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling to a patient in need thereof, alone or in combination with other cancer treatment. Non-limiting examples of an inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling include 4-[(1E)-2-[5,6-Dihydro-5,5-dimethyl-8-(2-phenylethynyl)-2-naphthalenyl]ethenyl]benzoic acid (commonly referred to as “BMS493”) and 4-[2-[5,6-Dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl] ethynyl]benzoic acid (commonly referred to as “AGN193109”). Alternatively, prior to administration of the inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling, a direct agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling may be administered to the patient.
Type:
Grant
Filed:
August 2, 2021
Date of Patent:
October 15, 2024
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Abstract: The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.
Abstract: The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
Abstract: A therapeutic treatment for preventing or reducing the formation of fibrosis comprising administering to a patient a UTX or JMJD3 inhibitor that are effective in preventing or reducing fibrosis in situations wherein access to an injury or dysmorphogenetic tissues before the fibrotic process becomes established in the tissues.
Type:
Grant
Filed:
July 7, 2022
Date of Patent:
September 10, 2024
Assignee:
Thomas Jefferson University
Inventors:
Janice L. Walker, Alexander Mazo, Svetlana Petruk, A. Sue Menko
Abstract: Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.
Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
Type:
Grant
Filed:
September 4, 2020
Date of Patent:
July 2, 2024
Assignee:
GW Pharma Limited
Inventors:
Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
Abstract: A method of treating recurrent spontaneous abortions or repeated implantation failures in a human female subject, comprising providing a composition including a combination of fatty acids or esters thereof as the active ingredients, wherein the human female subject has at least 12% of peripheral blood NK cells in total peripheral blood cells, and/or the cytotoxicity of the peripheral blood NK cells is at least 10% higher than a mean cytotoxicity of a control population of healthy human females of reproductive age without a reproductive failure and who have given birth to at least one child; orally administering the composition for 15 to 70 days, wherein the total amount of fatty acids or esters, administered per day, is from 0.03 g/kg 1 g/kg of body weight, calculated as fatty acids so as to reduce an immune-mediated sub-fertility for the human female subject.
Abstract: The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.
Abstract: The invention provides new substituted N9-adenine derivatives, pharmaceutical compositions containing these derivatives and the use of the new derivatives and the pharmaceutical compositions containing same as AMPK activators, being suitable for the production of drugs for the treatment of disorders and diseases where AMPK activation plays a relevant role.
Abstract: A percutaneous absorption preparation is disclosed. The percutaneous absorption preparation contains donepezil for treatment of dementia, wherein the preparation includes: (a) donepezil or its pharmaceutically acceptable salt as active component, (b) propylene glycol monocaprylate as solubilizer, and (c) styrene-isoprene-styrene block copolymer (“SIS”) as adhesive. The percutaneous absorption preparation has low skin irritation and high skin penetration.
Type:
Grant
Filed:
November 7, 2018
Date of Patent:
May 28, 2024
Assignees:
DONG-A ST CO., LTD., KM TRANSDERM LTD.
Inventors:
Sun-Woo Jang, Chang-Yell Shin, Jeong-Soo Kim, Hae-Sun Kim, Kwang-Ho Cha, Hyun-Jung Kim, Masaoki Goto
Abstract: Andrographolide 70 mg orally twice per day maintains normal health and body function in pediatric patients with Duchenne muscular dystrophy (DMD) and Becker's muscular dystrophy (BMD), and treats DMD/BMD.
Type:
Grant
Filed:
May 11, 2018
Date of Patent:
May 21, 2024
Assignee:
HP Ingredients Corp.
Inventors:
Juan O. Hancke, Enrique Brandan, Daniel Cabrera
Abstract: Antimicrobial diferulates, compositions containing same, and uses of same for inhibiting growth of microorganisms. The antimicrobial diferulates can be used alone or in combination with other antimicrobial agents to inhibit growth of microorganisms such as fungi, oomycetes, and other microorganisms having a glucan-containing cell wall. The antimicrobial diferulates can be included in pharmaceutical compositions for treatment of animals or included in agricultural compositions for treatment of plants, crops, and soils.
Type:
Grant
Filed:
August 27, 2021
Date of Patent:
May 21, 2024
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Jeff S. Piotrowski, Fachuang Lu, Mehdi Kabbage, John Ralph, Robert C. Landick
Abstract: Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.
Type:
Grant
Filed:
September 1, 2020
Date of Patent:
April 30, 2024
Assignee:
Sintetica S.A.
Inventors:
Augusto Mitidieri, Elisabetta Donati, Clara Bianchi
Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Type:
Grant
Filed:
December 15, 2022
Date of Patent:
April 9, 2024
Assignee:
Duke University
Inventors:
Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a thiopyrimidinone structure which function as inhibitors of ALDH protein, and their use as therapeutics for the treatment of cancer and other diseases.
Type:
Grant
Filed:
June 20, 2017
Date of Patent:
April 2, 2024
Assignees:
The Regents of the University of Michigan, Indiana University Research and Technology Corporation
Inventors:
Scott D. Larsen, Brandt C. Huddle, Kun Yang, Ronald Buckanovich, Thomas Hurley
Abstract: The present invention provides a method of treating liver fluke infections in a mammal in need of such treatment comprising administering an effective amount of diamphenethide in combination with an effective amount of clorsulon.
Type:
Grant
Filed:
September 30, 2019
Date of Patent:
March 26, 2024
Assignee:
Elanco Tiergesundheit AG
Inventors:
Sarah George, Peter Rolfe, Chouaib Tahtaoui
Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
Type:
Grant
Filed:
June 24, 2022
Date of Patent:
February 27, 2024
Assignee:
SIRNA THERAPEUTICS, INC.
Inventors:
Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
Abstract: Amino acid composition for use in the treatment of mucositis in patients suffering from head and neck cancer, undergoing radiation therapy and/or chemotherapy, the composition comprising an active agent, the active agent comprising the amino acids: glutamine, leucine, isoleucine, valine, lysine, threonine, histidine, phenylalanine, methionine, tryptophan, tyrosine, and cystine, wherein the glutamine:leucine weight ratio is in the range 4.3 to 5.3.
Abstract: The present invention relates to a combination of a histone deacetylase (HDAC) inhibitor, chidamide in an acidic salt form, and a nonsteroidal anti-inflammatory drugs (NSAIDs), celecoxib in a basic salt form. The present invention also relates to methods which significantly regulate tumor microenvironment and therefore dramatically improve anti-cancer activity.
Type:
Grant
Filed:
September 10, 2019
Date of Patent:
January 23, 2024
Assignee:
GREAT NOVEL THERAPEUTICS BIOTECH & MEDICALS CORPORATION